PD-1 inhibitor plus progesterone for fertility preservation in MMRd endometrial cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have been diagnosed with stage IA endometrial cancer (the earliest stage) that is grade 1 or 2 (less aggressive).
- Your tumor is MMR-deficient, which means it has a specific genetic feature that may respond better to immunotherapy.
- You have a strong desire to preserve your fertility (keep the ability to get pregnant).
- You have not had any other cancer, and you are not currently pregnant or unable to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
This trial tests a combination of two medicines (camrelizumab and anlotinib) for endometrial cancer that has spread back or continued and has specific tumor gene changes called MMRd. It may help shrink tumors or control the disease by activating the immune system and blocking cancer growth signals.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.